Clinical Outcomes Assessment (COA) Strategy & Gap Analysis for Regulatory Success

What Is a COA Strategy Gap Analysis?

A COA gap analysis evaluates whether your current clinical outcome assessments, including patient-reported outcomes (PROs) and other endpoint measures, are fit for purpose in clinical development and regulatory submissions.

We assess:

  • Relevance of selected endpoints to patient experience

  • Evidence supporting content validity and measurement properties

  • Alignment with FDA and EMA guidance

  • Readiness for regulatory and payer decision-making

Why COA Strategy Matters in Clinical Development

Without a robust COA strategy:

  • Endpoints may not support labeling claims

  • Patient experience data may lack regulatory relevance

  • Evidence gaps can delay approval or limit market access

A well-defined COA strategy ensures:

  • Clinically meaningful endpoints

  • Regulatory-grade evidence generation

  • Strong alignment with patient-focused drug development (PFDD)

Our COA Strategy Gap Analysis Approach

We provide structured, regulatory-focused support across all stages of clinical development:

Evidence Review

  • Review existing COA endpoint strategy

Gap Identification

  • Benchmark against regulatory expectations to identify missing evidence

  • Assess risks for regulatory submission

Strategic Recommendations

  • Define fit-for-purpose COA strategy

  • Recommend endpoint refinements and evidence generation plans

Regulatory Alignment

  • Align strategy with FDA patient-focused drug development guidance

  • Prepare for interactions with regulatory agencies

When Do You Need a COA Gap Analysis?

This service is particularly relevant if you:

  • Are preparing for Phase II or Phase III clinical trials

  • Plan regulatory submission with COA-based endpoints

  • Need to strengthen patient-reported outcomes (PROs)

  • Want to ensure alignment with FDA or EMA expectations

  • Have legacy endpoints with unclear validation status

Outcomes for Your Development Program

Our COA strategy and gap analysis enables:

  • Reduced regulatory risk

  • Clear, defensible endpoint strategy

  • Stronger evidence for payer and HTA decision-making

  • Improved integration of patient experience into clinical development

Why Work with us?

  • Deep expertise in clinical outcomes assessment (COA)

  • Focus on patient-centered evidence generation

  • Experience aligning strategies with FDA and EMA requirements

  • Tailored support for pharma and biotech development teams